Vera Therapeutics stock sinks following competitor’s successful trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
JPMorgan Defending Vera Therapeutics (VERA): 'pre-market weakness is overdone'
June 6, 2025 9:45 AM EDTJPMorgan analyst Anupam Rama reiterated an Overweight rating and $68.00 price target on Vera Therapeutics (NASDAQ: VERA).
The analyst comments "We view the downside in VERA shares pre-market as overdone given: 1) the totality of VERAs own phase 3 data for atacicept presented earlier this week (which was very solid), 2) our view that profiles of atacicept / sibeprenlimab are likely more similar than different on the clinical side (key considerations... More
Raymond James on Vera Therapeutics (VERA): 'we don’t think this is a referendum on the overall efficacy of these drugs in IgAN'
June 6, 2025 8:43 AM EDTRaymond James analyst Ryan Deschner reiterated a Strong Buy rating and $73.00 price target on Vera Therapeutics (NASDAQ: VERA).
The analyst comments "Otsuka reported a 51.2% placebo-adjusted proteinuria reduction for its Phase 3 VISIONARY study in IgAN at ERA today. While this result is numerically higher than what VERA reported earlier... More
Guggenheim on Vera Therapeutics (VERA): 'we would be incremental buyers on any weakness'
June 6, 2025 8:17 AM EDTGuggenheim analyst Vamil Divan reiterated a Buy rating and $65.00 price target on Vera Therapeutics (NASDAQ: VERA).
The analyst comments "Otsuka's (4578-JP) sibeprenlimab Phase 3 data presented at ERA this morning demonstrated impressive 51.2% placebo-adjusted proteinuria reduction in IgAN, numerically exceeding atacicept's 42% result, but we believe the competitive positioning remains more nuanced than headline efficacy numbers suggest. While sibeprenlimab's efficacy represents the strongest numerical result reported to date in IgAN Phase 3 trials, the... More
TD Cowen Reiterates Buy Rating on Vera Therapeutics (VERA)
June 6, 2025 8:15 AM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $60.00 price target on Vera Therapeutics (NASDAQ: VERA).
The analyst comments "The News: This morning at ERA, IgAN competitor Otsuka presented late breaking 36wk data from their ongoing Ph3 APRIL-only-inhibitor sibeprenlimab trial in IgAN. Data showed LSM 51.2% UPCR reduction (-50.2% sibe' vs +2.1% PBO). Safety was overall benign, with sibe' well tolerated. Injection site pain was slightly higher in the tx arm (13.2% vs 10.7% PBO), likely due to large injection volume. The presenter called out the imbalance of COVID-19 infections (12.5% vs 7.1% PBO), although argued no... More
Evercore ISI Reiterates Outperform Rating on Vera Therapeutics (VERA)
June 6, 2025 8:14 AM EDTEvercore ISI analyst Liisa Bayko reiterated an Outperform rating and $75.00 price target on Vera Therapeutics (NASDAQ: VERA)
The analyst comments "LIVE FROM VIENNA SLIDES INSIDE + live KOL event Our key takeaway? There are two good B cell modulators for patients. Details Early this... More
